These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30179109)
1. Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Sartoris R; Rautou PE; Elkrief L; Pollorsi G; Durand F; Valla D; Spahr L; Terraz S; Soubrane O; Cauchy F; Vilgrain V; Ronot M Radiology; 2018 Dec; 289(3):698-707. PubMed ID: 30179109 [TBL] [Abstract][Full Text] [Related]
2. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. Souhami A; Sartoris R; Rautou PE; Cauchy F; Bouattour M; Durand F; Giannelli V; Gigante E; Castera L; Valla D; Soubrane O; Vilgrain V; Ronot M JHEP Rep; 2020 Oct; 2(5):100147. PubMed ID: 32885156 [TBL] [Abstract][Full Text] [Related]
3. Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. De Vos N; Sartoris R; Cauchy F; Rautou PE; Vilgrain V; Ronot M Abdom Radiol (NY); 2020 Feb; 45(2):365-372. PubMed ID: 31797023 [TBL] [Abstract][Full Text] [Related]
4. Diagnosis of Clinically Significant Portal Hypertension Using CT- and MRI-based Vascular Model. Wang C; Huang Y; Liu C; Liu F; Hu X; Kuang X; An W; Liu C; Liu Y; Liu S; He R; Wang H; Qi X Radiology; 2023 Apr; 307(2):e221648. PubMed ID: 36719293 [TBL] [Abstract][Full Text] [Related]
5. CT-based liver surface nodularity for the detection of clinically significant portal hypertension: defining measurement quality criteria. Sartoris R; Lazareth M; Nivolli A; Dioguardi Burgio M; Vilgrain V; Ronot M Abdom Radiol (NY); 2020 Sep; 45(9):2755-2763. PubMed ID: 32270261 [TBL] [Abstract][Full Text] [Related]
6. Liver Surface Nodularity Quantification from Routine CT Images as a Biomarker for Detection and Evaluation of Cirrhosis. Smith AD; Branch CR; Zand K; Subramony C; Zhang H; Thaggard K; Hosch R; Bryan J; Vasanji A; Griswold M; Zhang X Radiology; 2016 Sep; 280(3):771-81. PubMed ID: 27089026 [TBL] [Abstract][Full Text] [Related]
7. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790 [TBL] [Abstract][Full Text] [Related]
8. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis. Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451 [TBL] [Abstract][Full Text] [Related]
10. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641 [TBL] [Abstract][Full Text] [Related]
11. Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Simbrunner B; Marculescu R; Scheiner B; Schwabl P; Bucsics T; Stadlmann A; Bauer DJM; Paternostro R; Eigenbauer E; Pinter M; Stättermayer AF; Trauner M; Mandorfer M; Reiberger T Liver Int; 2020 Jul; 40(7):1713-1724. PubMed ID: 32358998 [TBL] [Abstract][Full Text] [Related]
12. Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. Liu Y; Ning Z; Örmeci N; An W; Yu Q; Han K; Huang Y; Liu D; Liu F; Li Z; Ding H; Luo H; Zuo C; Liu C; Wang J; Zhang C; Ji J; Wang W; Wang Z; Wang W; Yuan M; Li L; Zhao Z; Wang G; Li M; Liu Q; Lei J; Liu C; Tang T; Akçalar S; Çelebioğlu E; Üstüner E; Bilgiç S; Ellik Z; Asiller ÖÖ; Liu Z; Teng G; Chen Y; Hou J; Li X; He X; Dong J; Tian J; Liang P; Ju S; Zhang Y; Qi X Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2998-3007.e5. PubMed ID: 32205218 [TBL] [Abstract][Full Text] [Related]
13. Liver Surface Nodularity Score Allows Prediction of Cirrhosis Decompensation and Death. Smith AD; Zand KA; Florez E; Sirous R; Shlapak D; Souza F; Roda M; Bryan J; Vasanji A; Griswold M; Lirette ST Radiology; 2017 Jun; 283(3):711-722. PubMed ID: 27809664 [TBL] [Abstract][Full Text] [Related]
14. Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4. Banini BA; Patel S; Yu JW; Kang L; Bailey C; Strife BJ; Siddiqui MS; Patel V; Matherly SC; Lee H; Lewis S; Cherian R; Stravitz RT; Luketic V; Sanyal AJ; Sterling RK J Clin Gastroenterol; 2023 Feb; 57(2):189-197. PubMed ID: 34999644 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. Liu F; Ning Z; Liu Y; Liu D; Tian J; Luo H; An W; Huang Y; Zou J; Liu C; Liu C; Wang L; Liu Z; Qi R; Zuo C; Zhang Q; Wang J; Zhao D; Duan Y; Peng B; Qi X; Zhang Y; Yang Y; Hou J; Dong J; Li Z; Ding H; Zhang Y; Qi X EBioMedicine; 2018 Oct; 36():151-158. PubMed ID: 30268833 [TBL] [Abstract][Full Text] [Related]
17. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India. Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976 [TBL] [Abstract][Full Text] [Related]
18. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. Qi X; An W; Liu F; Qi R; Wang L; Liu Y; Liu C; Xiang Y; Hui J; Liu Z; Qi X; Liu C; Peng B; Ding H; Yang Y; He X; Hou J; Tian J; Li Z Radiology; 2019 Feb; 290(2):370-377. PubMed ID: 30457484 [TBL] [Abstract][Full Text] [Related]
19. CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma. Romero-Cristóbal M; Clemente-Sánchez A; Ramón E; Téllez L; Canales E; Ortega-Lobete O; Velilla-Aparicio E; Catalina MV; Ibáñez-Samaniego L; Alonso S; Colón A; Matilla AM; Salcedo M; Albillos A; Bañares R; Rincón D JHEP Rep; 2023 Mar; 5(3):100645. PubMed ID: 36691569 [TBL] [Abstract][Full Text] [Related]
20. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]